![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
Division of Pharmacology and Chemotherapy, Department of Internal Medicine (M.F., C.B., L.A., R.C., M.D.T.), Department of Human Morphology and Applied Biology, Section of Histology and General Embryology (N.B., C.S.), University of Pisa, Pisa, Italy; and Department of Pharmacology (F.D.P.), University of Bologna, Bologna, Italy
Received for publication
November 11, 2005
Accepted
February 7, 2006.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
; Fornai et al., 2005b), whereas in the presence of ulcer, inflammatory, or neoplastic diseases, COX-2 expression can be up-regulated. In these settings, COX isoforms may play differential pathophysiological roles, such as the involvement of COX-1 and COX-2 in the development of gastrointestinal damage induced by nonsteroidal anti-inflammatory drugs (Tanaka et al., 2002), and the carcinogenesis and tumor cell proliferation promoted by COX-2-derived prostanoids (Subbaramaiah and Dannenberg, 2003). In contrast, the pattern of COX isoform expression in gut neuromuscular layers remains to be clarified. Previous reports described a significant COX-2 expression in colonic myenteric plexus and myocytes of various species, including humans, under normal conditions (Porcher et al., 2004; Fornai et al., 2005a), whereas other authors reported a scarce or absent expression (Roberts et al., 2001; Schwarz et al., 2001).
Intestinal inflammation is associated with alterations of gut motility and may contribute to the development of digestive symptoms (Collins, 1996). The mechanisms underlying dysmotility are still uncertain, but altered functions of myenteric nerves and smooth muscle have been observed (Sharkey and Kroese, 2001). Previous studies reported that COX pathways are involved in the modulation of normal gastrointestinal motility (Porcher et al., 2002, 2004; Fornai et al., 2005a), and that in the presence of intestinal inflammatory reactions, COX-2 might contribute to the pathophysiology of related motor alterations (Schwarz et al., 2001; Linden et al., 2004). For instance, experimental ileus in rats, evoked by intestinal manipulation, was associated with enteric COX-2 induction, and treatments with selective COX-2 inhibitors significantly improved the intestinal contractile activity, both in vivo and in vitro (Schwarz et al., 2001). Moreover, experimental colitis induced by trinitrobenzenesulfonic acid in guinea pigs is characterized by increased COX-2 expression in the colonic wall, and the products of this enzyme seem to be responsible for an enhanced excitability of myenteric AH neurons. In this model, the inhibition of COX-2, but not COX-1, restored the normal electrical properties of AH neurons, whereas the application of prostaglandin E2 to inflamed colonic preparations decreased the afterhyperpolarization of AH neurons and slowed their accommodation rate (Manning et al., 2002; Linden et al., 2004). However, there is still uncertainty on the role of COX isoforms in motor alterations associated with chronic intestinal inflammation and on the hypothesis that COX-derived mediators may regulate differently gut motility under physiological or pathological conditions (Costa, 2004).
The present study was designed to compare the role of COX isoforms in the control of neuromuscular functions in normal rats and after the induction of colitis. For this purpose, we examined the expression and localization of COX-1 and COX-2 in the colonic neuromuscular layer and the effects of COX blockade on in vitro colonic motor activity, using selective and nonselective COX-inhibitors.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Induction and Assessment of Colitis. Colitis was induced in accordance with the method described previously by Barbara et al. (2000). In brief, during anesthesia with diethyl ether, 30 mg of 2,4-dinitrobenzenesulfonic acid (DNBS) in 0.25 ml of 50% ethanol was administered intrarectally via a polyethylene PE-60 catheter inserted 8 cm proximal to the anus. Control rats received 0.25 ml of saline. Animals underwent subsequent experimental procedures 6 days after DNBS administration to allow a full development of histologically evident colonic inflammation. At that time, the animals were euthanized, and the severity of intestinal inflammation was evaluated macroscopically and histologically in accordance with the criteria previously reported by Wallace and Keenan (1990), as modified by Barbara et al. (2000). The macroscopic criteria were based on the following: presence of adhesions between colon and other intra-abdominal organs, consistency of colonic fecal material (indirect marker of diarrhea), thickening of colonic wall, presence and extension of hyperemia, and macroscopic mucosal damage (assessed with the aid of a ruler). Microscopic criteria were assessed by light microscopy on hematoxylin- and eosin-stained sections obtained from whole-gut specimens, taken from a region of inflamed colon immediately adjacent to the gross macroscopic damage and fixed in cold 4% neutral formalin diluted in phosphate-buffered saline (PBS). Histological criteria included: degree of mucosal architecture changes, cellular infiltration, external muscle thickening, presence of crypt abscess, and goblet cell depletion. All parameters of macroscopic and histological damage were recorded and scored for each rat by two observers blinded to the treatment.
Reverse Transcription-Polymerase Chain Reaction. Expression of mRNA coding for COX isoforms was assessed by reverse transcription (RT)-polymerase chain reaction (PCR). The analysis was performed on colonic specimens excised as reported above, subjected to mucosa and submucosa removal, snap-frozen in liquid nitrogen, and stored at –80°C. At the time of extraction, tissue samples were disrupted with cold glass pestles, and total RNA was isolated by TRIzol (Life Technologies, Carlsbad, CA) and chloroform. Total RNA (1 µg) served as template for cDNA synthesis in a reaction using 2 µl of random hexamers (0.5 µg/µl) with 200 U of Moloney murine leukemia virus-reverse transcriptase in a buffer containing 500 µM deoxynucleoside-5'-triphosphate (dNTP) and 10 mM dithiothreitol. cDNA samples were subjected to PCR in the presence of primers based on cloned rat COX isoforms (Tanaka et al., 2002). PCR, consisting of 5 µl of RT products, 2.5 U of Taq polymerase, 100 µM dNTP, and 0.5 µM primers, was carried out by a PCR-Express thermocycler (Hybaid, Ashford, Middlesex, UK). After 3 min at 94°C, the cycle conditions were 1 min at 94°C, 1 min at 55°C, and 1 min at 72°C for 30 cycles, followed by 7 min at 72°C. Aliquots of RNA not subjected to RT were included in PCR reactions to verify the absence of genomic DNA. The efficiency of RNA extraction, RT, and PCR was evaluated by primers for rat 
-actin. PCR products were separated by 1.8% agarose gel electrophoresis in a Tris buffer (40 mM) containing 2 mM EDTA, 20 mM acetic acid (pH 8), and stained with ethidium bromide. PCR products were then visualized by UV light and subjected to densitometric analysis by Kodak Image Station program (Eastman Kodak Co., Rochester, NY). The relative expression of target mRNA was normalized to that of -actin.
Immunohistochemical Analysis. Specimens of colonic tissue, excised and fixed as reported above, were dehydrated with ethanol, treated with xylene, and embedded in paraffin at 56°C. Serial sections (5 µm thick) were processed for immunostaining. Slides were treated with 1% hydrogen peroxide in methanol, microwaved in citrate buffer, and blocked with normal swine serum (1:20; Dakopatts, Glostrup, Denmark). Sections were then incubated overnight at 4°C with the following polyclonal primary antibodies: rabbit anti-COX-1 (1:200; code 160109; Cayman Chemical Company, Ann Arbor, MI), rabbit anti-COX-2 (1:3000; code no. ALX 210711; Alexis Biochemicals, Lausen, Switzerland), and rabbit antineurofilament (1: 4000; Chemicon, code no. AB 1987, Temecula, CA). Immunoglobulins were diluted in PBS with 0.1% bovine serum albumin and 0.1% sodium azide. Sections were washed with PBS and incubated with biotinylated immunoglobulins followed by peroxidase-labeled streptavidin complex and 3,3'-diaminobenzidine tetrahydrochloride (DAB; Dakopatts) (Bernardini et al., 1999). Sections were counter-stained with hematoxylin. All reactions were carried out at room temperature in a humidified chamber, and PBS was used for washes, unless otherwise specified. Negative controls were obtained by omitting primary antibodies or substituting the primary antibody with rabbit preimmune serum. Specificity of COX immunoreacting staining was assessed by preadsorbing anti-COX-1 and -COX-2 antibodies with COX-1 (code no. CAY 360109; Cayman Chemical Company) and COX-2 (code no. ALX 153-063; Alexis Biochemicals) blocking peptides, respectively, at 10 times the antibody concentrations for 24 h at 4°C. To test endogenous peroxidases and avidin-binding activity, slides were incubated only with DAB or streptavidin-peroxidase complex plus DAB, respectively.
Recording of Longitudinal Muscle Contractile Activity. The contractile activity of colonic longitudinal smooth muscle was recorded as described previously by Blandizzi et al. (2003). Specimens of colon, excised as reported above, were placed into ice-cold preoxygenated Krebs' solution, opened along the mesenteric insertion, and subjected to removal of mucosal/submucosal layer. The specimens were then cut along the longitudinal axis into strips of approximately 3-mm width and 20-mm length. The preparations were set up in 10-ml organ baths containing Krebs' solution at 37°C, bubbled with 95% O2 + 5% CO2, connected to isotonic transducers (Basile, Comerio, Italy) under a constant load of 1 g, and allowed to equilibrate for 30 min. Since there was no need to discriminate between active and passive tension developed by intestinal muscle, isotonic transducers were used to estimate changes in smooth muscle elongation under constant tension in response to stimulation. Krebs' solution had the following composition: 113 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, and 11.5 mM glucose, pH 7.4 ± 0.1. The contractile activity was recorded by a polygraph (Basile). A pair of coaxial platinum electrodes was positioned at distance of 10 mm from longitudinal axis of each preparation to deliver TES by a BM-ST6 stimulator (Biomedica Mangoni, Pisa, Italy). Stimuli were applied as 10-s single trains of square wave pulses (0.5 ms, 30 mA, 10 Hz). Each preparation was repeatedly challenged with electrical stimulations, and experiments started when reproducible responses were obtained (usually after two to three stimulations).
In the first set of experiments, colonic preparations were exposed to indomethacin (COX-1/COX-2 inhibitor, 1 µM), 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole (SC-560; COX-1 inhibitor, 0.1 µM), or 5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone (DFU; COX-2 inhibitor, 1 µM) for 30 min before transmural electrical stimulation (TES). Preparations were incubated with test drugs along two 15-min consecutive periods with an intervening washing. Drug concentrations were selected on the basis of previous studies (Riendeau et al., 1997; Kato et al., 2001).
The second set of experiments was designed to assay COX inhibitors on contractile responses elicited by TES directed to cholinergic innervation. For this purpose, colonic preparations were maintained in Krebs' solution containing guanethidine (adrenergic blocker, 10 µM), N
-nitro-L-arginine methylester (L-NAME, inhibitor of nitricoxide synthase, 100 µM), L-732,138 (NK1 receptor antagonist, 10 µM), GR-159897 (NK2 receptor antagonist, 1 µM), and SB-218795 (NK3 receptor antagonist, 1 µM) to prevent noncholinergic motor responses (Fornai et al., 2005a). Incubation of colonic strips with COX inhibitors before challenge with TES was performed as reported above.
In the third series, COX inhibitors were assayed on cholinergic contractions elicited by direct pharmacological activation of muscarinic receptors on smooth muscle cells. Preparations were maintained in Krebs' solution containing tetrodotoxin (1 µM) and stimulated twice with carbachol (muscarinic receptor agonist, 1 µM). The first stimulation was applied in the absence of other drugs, whereas the second one was applied after 30-min incubation with COX inhibitors, as reported above.
In a fourth set of experiments, the effects of COX inhibitors on TES-evoked motor responses were assessed on colonic preparations obtained from control or DNBS-treated rats treated daily with superoxide dismutase (SOD; 7 mg/kg/day s.c.) (Segui et al., 2004) or S-methylisothiourea (SMT; 14 mg/kg/day s.c.), a selective inhibitor of inducible nitric-oxide synthase (iNOS) (Afulukwe et al., 2000), for 6 consecutive days starting 1 h before the induction of colitis.
Drugs and Reagents. Indomethacin, SC-560, atropine sulfate, hexamethonium bromide, N-nitro-L-arginine methylester, carbachol hydrochloride, guanethidine, superoxide dismutase, and S-methylisothiourea were from Sigma Chemical (St. Louis, MO); DFU was kindly provided by Merck Research Laboratories (Rahway, NJ); L-732,138, GR-159897, SB-218795, and tetrodotoxin were from Tocris Cookson (Bristol, UK); and random hexamers, Moloney murine leukemia virus-reverse transcriptase, Taq polymerase, and dNTP mixture were from Promega (Madison, WI). COX inhibitors were dissolved in dimethyl sulfoxide, and further dilutions were made with saline solution. Dimethyl sulfoxide concentration in organ bath never exceeded 0.5%.
Statistical Analysis. Results are given as mean ± S.E.M. The significance of differences was evaluated on raw data, prior to percentage normalization, by Student's t test for unpaired data or one-way analysis of variance followed by post hoc analysis with Student-Newman-Keuls test, and P < 0.05 was considered significant. Colonic preparations included in each test group were obtained from distinct animals; therefore, the number of experiments refers also to the number of animals assigned to each group. Calculations were performed by commercial software (Prism, version 3.0; GraphPad Software Inc., San Diego, CA).
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
|
RT-PCR Analysis. RT-PCR analysis revealed the expression of COX-1 and COX-2 in colonic neuromuscular layers of both normal and DNBS-treated animals (Fig. 1A). The densitometric analysis, performed on amplified cDNA bands, indicated a significant increase in the expression of COX-2 mRNA in the presence of colitis (Fig. 1C), whereas no appreciable changes in the expression of COX-1 were detected (Fig. 1B).
|
). Neurons of myenteric ganglia were localized by means of immunoreactivity to neurofilament both in normal (Fig. 2E) and inflamed (Fig. 2F) colon. Preadsorption of primary antibodies with the respective blocking peptides completely abolished any specific immunoreactivity (data not shown).
|
|
Effects of COX Inhibitors on Longitudinal Smooth Muscle Activity. During the equilibration period, most colonic preparations, obtained from normal or DNBS-treated rats, showed rapid and low in amplitude spontaneous activity, which remained stable throughout the experiment. TES-induced responses consisted of fast phasic contractions often followed by aftercontractions of variable amplitude (Fig. 4). The use of isotonic transducers allowed to record electrically evoked contractions as changes in smooth muscle elongation under constant tension, thus minimizing possible inflammation-induced variations of intrinsic contractile activity. Accordingly, control responses of normal tissues did not differ significantly from those observed in colonic preparations from DNBS-treated rats. Preincubation with atropine (1 µM) inhibited phasic contractions or converted them into relaxations, and only aftercontractions were evident. Tetrodotoxin (1 µM) abolished the contractile responses evoked by TES (not shown).
|
|
Exposure of colonic preparations, from normal or DNBS-treated animals, to carbachol (1 µM) resulted in phasic contractions (Fig. 6) sensitive to atropine. Under these conditions, carbachol-induced responses were not affected by indomethacin (1 µM) either in the absence or in the presence of colitis (Fig. 6). Similarly, SC-560 (0.1 µM), DFU (1 µM), or SC-560 plus DFU did not modify the motor responses elicited by carbachol (Fig. 6).
|
When colonic preparations, isolated from animals treated with DNBS plus SOD, were exposed to indomethacin (1 µM), the contractile responses evoked by TES were significantly increased (+66%) (Fig. 7A). Under these conditions, SC-560 (0.1 µM) or DFU (1 µM) significantly enhanced TES-evoked motor activity, although they were less effective than indomethacin (+28 and +46%, respectively) (Fig. 7A). Coincubation of colonic tissues with SC-560 plus DFU resulted in increments of TES-induced contractions similar to those observed in the presence of indomethacin alone (+69%) (Fig. 7A). In colonic tissues from rats with colitis subjected to in vivo iNOS blockade by SMT, COX inhibitors enhanced TES-induced contractions, with response patterns similar to those recorded after treatment of animals with DNBS plus SOD (Fig. 7B). Incubation of colonic tissues, obtained from normal rats treated with SOD or SMT, with COX inhibitors, resulted in enhancements of TES-induced contractions that did not differ significantly from those observed in the absence of SOD or SMT.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
, 2004; Fornai et al., 2005a) and could play a role in the control of myenteric nerve function during intestinal inflammation. In line with this view, Roberts et al. (2001) demonstrated increased COX-2 immunoreactivity in colonic myenteric neurons of patients with ulcerative colitis or Crohn's disease, and Schwarz et al. (2001) found enhancement of COX-2 immunostaining in neurons and smooth muscle cells from jejunal tissues of rats undergoing intestinal manipulation (an experimental model of postoperative ileus).
The pharmacological blockade of COX isoforms in normal colonic preparations significantly increased electrically induced contractions, especially after pharmacological ablation of noncholinergic nerve pathways. Electrically evoked cholinergic contractions were enhanced after exposure to either SC-560 (COX-1 inhibitor) or DFU (COX-2 inhibitor). Even more pronounced effects (of similar magnitude) were recorded with the nonselective inhibitor indomethacin and with combined blockade of both COX isoforms by SC-560 plus DFU.
The present findings strengthen the notion that COX-derived products can modulate enteric cholinergic neurotransmission in the normal gut. De Backer et al. (2003) reported that indomethacin enhances the electrically induced acetylcholine release in muscle strips of pig stomach, suggesting inhibition by prostanoids of intramural cholinergic neurons. Furthermore, we previously observed that selective and nonselective COX inhibitors potentiate electrically induced cholinergic contractions of smooth muscle strips prepared from human distal colon (Fornai et al., 2005a). In contrast with findings in humans, pigs, and rats, experiments performed on guinea pig intestine indicated that the electrically or nicotine-induced acetylcholine release and related cholinergic contractions are enhanced by application of exogenous prostaglandins and inhibited by indomethacin, suggesting that in this species, endogenous prostanoids mediate excitation of cholinergic enteric pathways (Takeuchi et al., 1991). Therefore, the effects of prostanoids and COX inhibitors on gut motility depend on species, gut region, and muscular layer.
Our observation that TES- but not carbachol-induced contractions were affected by COX blockade indicates that the modulating control of COX pathways on cholinergic motor activity occurs at neuronal rather than at muscular sites. These functional data are consistent with our molecular analysis showing that both COX-1 and COX-2 were detected predominantly in neurons of myenteric ganglia, with no appreciable immunostaining in the muscular layers. Thus, it is conceivable that prostanoids produced by COX-1 and COX-2, both located in myenteric neurons, inhibit colonic cholinergic neurotransmission. In line with this proposal, preliminary in vivo experiments performed in our laboratory indicated that colonic transit in normal animals was enhanced by either COX-1 or COX-2 blockade, whereas COX-1 inhibition was without effect in rats with colitis (M. Fornai, L. Antonioli, R. Colucci, C. Blandizzi, and M. Del Tacca, unpublished data).
In colonic preparations obtained from rats with colitis, SC-560 lost its enhancing effect on electrically induced cholinergic contractions, whereas increments of similar degree were observed upon application of indomethacin, DFU, or indomethacin plus DFU. The modulating function of COX-2 was likely to occur still at neuronal level because neither indomethacin nor DFU affected carbachol-induced contractions.
An intriguing finding in rats with colitis is that the functional data are not fully consistent with the patterns of COX isoform localization; although expression of COX-2 increased, the motor enhancing effects resulting from its pharmacological inhibition remained nearly unchanged. On the other hand, COX-1 expression did not vary, but its blockade was without effects on the evoked cholinergic contractions. To get further insight into this aspect, it is noteworthy that gut inflammation is associated with increased production of reactive oxygen species, such as superoxide anion radicals (
) and peroxynitrite anions (ONOO–), known to induce oxidative tissue injury (Dijkstra et al., 1998), and that peroxynitrite anions, generated from the reaction between nitric oxide (NO) and superoxide anions, can down-regulate the catalytic activities of COX enzymes, especially COX-1 (Fujimoto et al., 2004). Accordingly, antioxidants were reported to ameliorate experimental colitis (Segui et al., 2004; Oz et al., 2005). Thus, it is conceivable that, in the presence of colitis, increased production of peroxynitrite anions could functionally inactivate COX-1 activity, whereas COX-2 overexpression could remain functionally silent because of the inhibition exerted by reactive oxygen species. To test this hypothesis, we performed functional experiments on colonic preparations obtained from rats with colitis treated with SOD (the enzyme responsible for O –2 inactivation) or SMT (a selective inhibitor of iNOS, the main source of NO in inflamed tissues). Thus, evidence was obtained that the in vivo antioxidant treatment with SOD or SMT could prevent COX-1 inactivation. Indeed, under these conditions, SC-560 almost completely recovered its ability to enhance the electrically evoked contractions of colonic longitudinal muscle strips.
Taking together our molecular and pharmacological findings, it appears that, in the presence of inflammation, changes in the control of colonic motility by COX pathways reflect mainly impaired function of these enzymes because of increased oxidative stress. Thus, as postulated by Costa (2004), COX-derived mediators do not seem to play distinct physiological and pathological roles, at least in the case of gut motility, and the induction of COX-2 expression by intestinal inflammation might be viewed as an attempt of endogenous homeostatic mechanisms to preserve or restore the modulating actions of COX products.
In conclusion, this study indicates that both COX-1 and COX-2 are constitutively expressed in the neuromuscular layer of normal rat colon, where they are mainly localized in neurons of myenteric ganglia and contribute to inhibition of excitatory cholinergic pathways. In the presence of colitis, the COX-2 isoform seems to play a predominant role in driving this modulating action.
|
Footnotes |
|---|
ABBREVIATIONS: COX, cyclooxygenase; DNBS, 2,4-dinitrobenzenesulfonic acid; PBS, phosphate-buffered saline; RT, reverse transcription; PCR, polymerase chain reaction; dNTP, deoxynucleoside-5'-triphosphate; DAB, 3,3'-diaminobenzidine tetrahydrochloride; TES, transmural electrical stimulation; SC-560, 5-(4-chloro-phenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole; DFU, 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone; L-NAME, N-nitro-L-arginine methylester; L-732,138, N-acetyl-L-tryptophan 3,5-bis(trifluoromethyl)benzyl ester; GR-159897, 5-fluoro-3-[2-[4-methoxy-4-[[(R)-phenylsulphinyl]methyl]-1-piperidinyl]ethyl]-1H-indole; SB-218795, (R)-[[2-phenyl-4-quinolinyl)carbonyl]amino]-methyl ester benzeneacetic acid; SOD, superoxide dismutase; SMT, S-methylisothiourea; iNOS, inducible nitric-oxide synthase.
Address correspondence to: Prof. Corrado Blandizzi, Divisione di Farmacologia e Chemioterapia, Dipartimento di Medicina Interna, Università di Pisa, Via Roma, 55, 56126 Pisa, Italy. E-mail: c.blandizzi{at}virgilio.it
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Afulukwe IF, Cohen RI, Zeballos GA, Iqbal M, and Scharf SM (2000) Selective NOS inhibition restores myocardial contractility in endotoxemic rats: however, myocardial NO content does not correlate with myocardial dysfunction. Am J Respir Crit Care Med 162: 21–26.
Barbara G, Xing Z, Hogaboam CM, Gauldie J, and Collins SM (2000) Interleukin 10 gene transfer prevents experimental colitis in rats. Gut 46: 344–349.
Bernardini N, Bianchi F, and Dolfi A (1999) Laminin and beta1 integrin distribution in the early stages of human kidney development. Nephron 81: 289–295.[CrossRef][Medline]
Blandizzi C, Fornai M, Colucci R, Baschiera F, Barbara G, De Giorgio R, De Ponti F, Breschi MC, and Del Tacca M (2003) Altered prejunctional modulation of intestinal cholinergic and noradrenergic pathways by 
2-adrenoceptors in the presence of experimental colitis. Br J Pharmacol 139: 309–320.[CrossRef][Medline]
Collins SM (1996) The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 111: 1683–1699.[CrossRef][Medline]
Costa M (2004) COX and the gut: now we see it now we don't. Neurogastroenterol Motil 16: 693–695.[CrossRef][Medline]
De Backer O, Leclere PG, and Lefebvre RA (2003) Pharmacological characterization of pre- and postsynaptic prostanoid receptors in pig gastric fundus. Neuropharmacology 45: 684–690.[CrossRef][Medline]
Dijkstra G, Moshage H, Van Dullemen HM, De Jager-Krikken A, Tiebosch ATMG, Kleibeuker JH, Jansen PLM, and Van Goor H (1998) Expression of nitric oxide synthase and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. J Pathol 186: 416–421.[CrossRef][Medline]
Fornai M, Blandizzi C, Colucci R, Antonioli L, Bernardini N, Segnani C, Baragatti B, Barogi S, Berti P, Spisni R, et al. (2005a) Role of cyclooxygenase 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut 54: 608–616.
Fornai M, Natale G, Colucci R, Tuccori M, Carazzina G, Antonioli L, Baldi S, Lubrano V, Abramo A, Blandizzi C, et al. (2005b) Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. Naunyn-Schmiedeberg's Arch Pharmacol 372: 79–87.[Medline]
Fujimoto Y, Uno E, and Sakuma S (2004) Effects of reactive oxygen and nitrogen species on cyclooxygenase-1 and -2 activities. Prostaglandins Leukotrienes Essent Fatty Acids 71: 335–340.[CrossRef][Medline]
Kato M, Nishida S, Kitasato H, Sakata N, and Kawai S (2001) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol 53: 1679–1685.[CrossRef][Medline]
Linden DR, Sharkey KA, Ho W, and Mawe GM (2004) Cyclooxygenase-2 contributes to dysmotility and enhance excitability of myenteric AH neurones in the inflamed guinea pig distal colon. J Physiol (Lond) 557: 191–205.
Maihofner C, Tegeder I, Euchenhofer C, Dewitt D, Brune K, Bang R, Neuhuber W, and Geisslinger G (2000) Localization and regulation of cyclo-oxygenase-1 and -2 and neuronal nitric oxide synthase in mouse spinal cord. Neuroscience 101: 1093–1108.[CrossRef][Medline]
Manning BP, Sharkey KA, and Mawe GM (2002) Effects of PGE2 in guinea pig colonic myenteric ganglia. Am J Physiol 283: G1388–G1397.
Oz HS, Chen TS, McClain CJ, and de Villiers WJS (2005) Antioxidants as novel therapy in a murine model of colitis. J Nutr Biochem 16: 297–304.[CrossRef][Medline]
Porcher C, Horowitz B, Bayguinov O, Ward SM, and Sanders KM (2002) Constitutive expression and function of cyclooxygenase-2 in murine gastric muscle. Gastroenterology 122: 1442–1454.[CrossRef][Medline]
Porcher C, Horowitz B, Ward SM, and Sanders KM (2004) Constitutive expression and functional expression of cyclooxygenase 2 in the murine proximal colon. Neurogastroenterol Motil 16: 785–799.[CrossRef][Medline]
Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, et al. (1997) Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 121: 105–117.[CrossRef][Medline]
Roberts PJ, Morgan K, Miller R, Hunter JO, and Middleton SJ (2001) Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease. Gut 48: 468–472.
Schwarz NT, Kalff JC, Turler A, Engel BM, Watkins SC, Billiar TR, and Bauer AG (2001) Prostanoid production via COX-2 as a causative mechanism of rodent postoperative ileus. Gastroenterology 121: 1354–1371.[CrossRef][Medline]
Segui J, Gironella M, Sans M, Granell S, Gil F, Gimeno M, Coronel P, Pique JM, and Panes J (2004) Superoxide dismutase ameliorates TNBS-induced colitis by reducing oxidative stress, adhesion molecule expression and leukocyte recruitment into the inflamed intestine. J Leukoc Biol 76: 537–544.
Sharkey KA and Kroese ABA (2001) Consequences of intestinal inflammation on the enteric nervous system: neuronal activation induced by inflammatory mediators. Anat Rec 262: 79–90.[CrossRef][Medline]
Subbaramaiah K and Dannenberg AJ (2003) Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24: 96–102.[CrossRef][Medline]
Takeuchi T, Okuda M, and Yagasaki O (1991) The differential contribution of endogenous prostaglandins to the release of acetylcholine from the myenteric plexus of the guinea-pig ileum. Br J Pharmacol 102: 381–385.
Tanaka A, Hase S, Miyazawa T, and Takeuchi K (2002) Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 300: 754–761.
Wallace JL and Devchand PR (2005) Emerging roles for cyclooxygenase-2 in gastrointestinal mucosa defense. Br J Pharmacol 145: 275–282.[CrossRef]
Wallace JL and Keenan CM (1990) An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol 258: G527–G534.[Medline]
This article has been cited by other articles:
|
|
 |
|
  E. Burcher, F. Shang, F. J. Warner, Q. Du, D. Z. Lubowski, D. W. King, and L. Liu Tachykinin NK2 Receptor and Functional Mechanisms in Human Colon: Changes with Indomethacin and in Diverticular Disease and Ulcerative Colitis J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 170 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Birkenmeier, A. Staudt, W.-H. Schunck, I. Janke, C. Labitzke, T. Prange, C. Trimpert, T. Krieg, M. Landsberger, V. Stangl, et al. COX-2-dependent and potentially cardioprotective effects of negative inotropic substances released after ischemia Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2148 - H2154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Antonioli, M. Fornai, R. Colucci, N. Ghisu, F. Da Settimo, G. Natale, O. Kastsiuchenka, E. Duranti, A. Virdis, C. Vassalle, et al. Inhibition of Adenosine Deaminase Attenuates Inflammation in Experimental Colitis J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 435 - 442. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
